Goldman Sachs analyst Andrea Newkirk initiated coverage of Kymera Therapeutics (KYMR) with an Early-Stage Biotech rating. The firm says Kymera is an early, clinical-stage biopharmaceutical company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Gilead estimates Q2 acquired IPR&D expenses of $61M
- Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow
- Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships
- Kymera Therapeutics assumed with an Overweight at Morgan Stanley
- Kymera Therapeutics management to meet with B. Riley